A pivotal phase 2 clinical trial designed to help Celgene (CELG) and Bluebird Bio (BLUE) secure approval for the first CAR-T therapy targeting multiple myeloma will begin enrolling patients next week.
A listing for the clinical trial of the CAR-T therapy known as BB2121 was posted to the government’s ClinicalTrials.gov website on Tuesday, with a planned start date of Dec. 11. Celgene licensed BB2121 from Bluebird and is the sponsor of the study, which the company is calling KarMMA.
About the Author Reprints
I’d like to see the CAR-T article.
Eric
I am a Multiple Myeloma and live in South Africa. I would like to know if any trials will be done in my Country.